Seta Clinic Tokyo

9.50

Tokyo, Japan

User Score	Rating	Price Range	Media Files	Certificates	Founded In	Patients	Ownership	Age Group	Clinic Type	Type of Care	Size	Online Consultations
89%	9.5/10	$$$	19	3	1999	870	Private hospital	Kids, Adults	Specialized	Outpatient	Small	Yes

Overview

Size

Small

Clinic type

Specialized

Type of care

Outpatient

Age group

Kids, Adults

Certificates

Features & Facts

Experienced provider

The clinic positions itself as an early specialized provider of cancer immuno-cell therapy in Japan, with operations starting in March 1999.

Comprehensive immunotherapy options

They are as follows: dendritic cell cancer vaccines (DCT), NKT cell therapy, alpha-beta T cell therapy, gamma delta T cell therapy, and NK cell therapy. An appropriate type of immuno-cell therapy for each patient, based on condition and primary treatment.

DC vaccine therapy in 3 delivery formats

The clinic uses tumor lysate from surgery, synthesized peptides (a conjunction of several to some dozen amino acids), or direct local injection for individual dendritic cell therapy.

Large cumulative treated population

The clinic states it has treated more than 23,000 patients (including patients from partner medical institutions) over the period from April 1999 to September 2025.

Detailed case mix by cancer type

As of the end of September 2025, the clinic publishes treated-patient counts by site, including lung (3,488), pancreas (2,949), colorectal (2,924), stomach (2,337), breast (1,582), ovary (1,281), uterus (1,197), and liver (1,187), among many other categories.

Cell expansion is quantified

In its processing description, the clinic cultures T-lymphocytes, which are expanded by roughly a thousand-fold over 2 weeks, and the infused quantity can reach nearly 5 billion cells.

Continuous environmental oversight

The clinic describes an IT-based 24-hour monitoring system tracking specific items, including storage temperatures for media/agents, CO₂ incubator temperature and carbon dioxide concentration, and temperatures in culturing and quality-control rooms.

Standardization across a broader clinical network

The group describes a multi-institutional clinical research structure (CITEG) launched in October 2015 with 50 medical institutions and states that data are collected from over 10,000 treatment cases per year within that network for analysis and publication.

Published treatment composition data in outcomes reporting

In a results summary, the clinic reports a cohort with 1,401 total patients, of whom 592 (42.3%) were “evaluable,” and within the evaluable set, 48.0% received immuno-cell therapy alone, while 52.0% received it combined with chemotherapy or radiation; it also reports modality counts such as CD3-LAK 526 (88.9%) among evaluable patients.

About the clinic

Seta Clinic Tokyo is presented as a specialty medical clinic focused on cancer care using immuno-cell therapy, a cell-based approach that uses a patient’s own immune cells. The clinic positions this as a systemic treatment option intended to support cancer management while prioritizing quality of life and aiming for comparatively limited adverse effects relative to many conventional systemic therapies. The clinical concept described centers on collecting immune cells from the patient, processing and expanding or activating them outside the body in a controlled cell-processing environment, and then administering the prepared cells back to the patient. The therapy is framed in immunological terms that distinguish between innate and adaptive immunity, and it includes both antigen-specific and antigen-nonspecific strategies, depending on the selected modality. The treatment menu is described as comprising multiple immune-cell modalities, including activated autologous lymphocyte approaches using T lymphocytes, dendritic cell vaccine approaches that aim to induce tumor-specific immune responses through antigen presentation, and specific lymphocyte subsets, such as αβ T-cell and γδ T-cell therapies. Additional immune-cell options described include NK-cell and NKT-cell therapies, with the emphasis that some regimens can be combined, such as pairing NKT-cell approaches with dendritic cell vaccines to engage both innate and adaptive immune responses. The patient pathway begins with a physician consultation that reviews the patient’s disease status and prior treatments and considers whether immuno-cell therapy is appropriate and how it should be positioned relative to other oncologic care. This is followed by blood collection, which may be performed as a standard blood draw or by apheresis, depending on the intended modality and cell type. The collected cells are then cultivated and prepared over roughly two weeks in a specialized processing facility before being administered back to the patient, typically as an outpatient regimen. A significant operational emphasis is placed on the cell-processing infrastructure and quality controls used for handling autologous cells. The processing environment is described as having controlled-room practices consistent with GMP concepts, standardized operating procedures intended to maintain consistent quality across locations, and continuous monitoring of key environmental and incubation conditions. The quality-management narrative also references ISO 9001 certification for supporting services and describes representative cleanroom-related features and equipment used in the cell-processing workflow. Eligibility and care-setting claims include that the therapies are generally positioned as outpatient-based and intended to be compatible with standard oncology care rather than mutually exclusive with it. Specific ineligibility criteria are described, including HIV antibody positivity and prior organ or bone-marrow transplant, and limitations are noted for certain hematologic malignancies. The clinic environment is appointment-based, with an emphasis on enabling longer, detailed discussions about treatment direction and accommodating family participation during consultations. Educational or informational formats, such as online information sessions and follow-up consultation opportunities, are also considered part of patient engagement.

Gallery

Extra services

Telemedicine

Post-Travel Follow-up

Support Groups

FAQ

What is Seta Clinic Tokyo best known for?

Seta Clinic Tokyo is a specialized clinic focused on Immuno-Cell Therapy, offering several immune-cell–based modalities for cancer-related care.

What cancers are covered?

The treatment is offered for most cancer types. Some hematologic (blood) cancers may be excluded, but in general, the clinic treats a broad range of solid tumors. Patients may be seen at different points in their disease course, including early-stage cases as well as recurrence or metastatic disease.

How does the treatment course typically work?

The clinic approach follows a repeating cycle of blood collection, cell cultivation, and infusion. A typical course consists of 6 administrations, performed at 2-week intervals over approximately 3 months.